Get the latest news, insights, and market updates on ENVB (Enveric Biosciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results
CAMBRIDGE, Mass., November 14, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced financial results for the third quarter ended September 30, 2025, and provided a comprehensive business update. Nov 14, 2025 - $ENVB
Enveric Biosciences Announces Reverse Stock Split
CAMBRIDGE, Mass., October 23, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 12 pre-split shares. The reverse stock split will become effective at 8:00 a.m., New York time, on Tuesday, October 28, 2025. Enveric’s co Oct 23, 2025 - $ENVB
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Ayr Wellness Advanced Debt Restructuring While Expanding Operations with New Florida Facility Vireo Growth Acquired Schwazze Debt in $62 Million Deal Tilray Expanded into Panama Through Joint Venture, Strengthening its Global Cannabis Footprint Key Takeaways; Psychedelic Sector Enveric Biosciences Expanded Neuroplastogenic Patent Estate and Strengthened IP Defense Amid Strategic Initiatives Algernon […] Oct 19, 2025 - $ENVB
Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance
CAMBRIDGE, Mass., October 16, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the issuance of its 23rd patent from the United States Patent and Trademark Office (USPTO) for novel compounds within its neuroplastogenic patent estate, further expanding its intellectual property assets for the potential treatment of mental heal Oct 16, 2025 - $ENVB
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal
CAMBRIDGE, Mass., October 15, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it has hired intellectual property powerhouse Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals (Gilgamesh) against Enveric’s issued U.S. Patent No. 12,138,276 (the’276 patent,) entitled, Oct 15, 2025 - $ENVB
Enveric Biosciences hires Fish & Richardson to defend patent tied to AbbVie deal
Investing.com -- Enveric Biosciences (NASDAQ: ENVB) has hired prominent intellectual property law firm Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals, which earlier this year agreed to be acquired by AbbVie for up to $1.2 billion, Investing.com has learned. Oct 15, 2025 - $ENVB
Enveric Biosciences to Explore Digital Asset Treasury Opportunities
CAMBRIDGE, Mass., October 14, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that its Board of Directors has authorized the Company’s Capital Markets Committee to explore and negotiate non-binding term sheets for potential Digital Asset Treasury (DAT) strategy opportunities. Any such opportunities will be subject to further Oct 14, 2025 - $ENVB
Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials
CAMBRIDGE, Mass., October 02, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced significant progress in the chemistry, manufacturing, and controls (CMC) development of its lead candidate, EB-003. Important steps in scaling production and preparing the drug for required regulatory activities have been achieved, advancing EB-003 Oct 2, 2025 - $ENVB
Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
CAMBRIDGE, Mass., September 18, 2025--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced exercise of certain outstanding series A warrants to purchase up to an aggregate of 1,212,499 shares of common stock of the Company and series B warrants to purchase up to an aggregate of 1,212,499 sha Sep 18, 2025 - $ENVB
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.